Statins prescribing to reduce the risk of cardiovascular events

Jan 30, 2023 | Generics, UK Brands

We’ve all read the latest from NICE on the revised recommendations for the use of Statins to reduce the risk of cardiovascular events.  It’s been widely shared that there are currently 10 million eligible patients in the UK, and this could rise to as many as 25 million with the new advice.  WaveData’s ScriptMap service tells us that a little over 95 million prescriptions were issued for Statins in the last full year of available data, so we could be looking at almost 240 million prescriptions under the new guidelines.

What does this mean for stakeholders across the industry?  Delving into the WaveData systems, we’ve pulled some interesting insights on Atorvastatin Tablets 20mg 28, the most commonly used Statin in the UK. This data highlights not only the opportunity for both Distributors and Pharmacies, but also the challenge for Generic Manufacturers when it comes to meeting the potential demand.  We’ll continue to track the long term pricing trend, it will be interesting to see the direction of the curve as demand increases.

Share This